News & Updates

An intensive targeting of low-density lipoprotein cholesterol (LDL-C) level (<55 mg/dL) reduces the risk of cardiovascular events at 3 years in patients with atherosclerotic cardiovascular disease (ASCVD) when compared with conventional targeting (<70 mg/dL), results of the Ez-PAVE trial have shown.

A China study has found a substantial incident burden of cardiovascular disease (CVD) in the general population, with the highest prevalence seen among males and older adults. Geographic disparities and seasonal variations in CVD incidence have also been observed.

A Hong Kong–Chinese (HK-Chinese) model achieves satisfactory accuracy in predicting 10-year atherosclerotic cardiovascular disease (ASCVD) risk in Chinese patients with schizophrenia-spectrum disorders, according to a population-based cohort study.

Finerenone significantly reduces albuminuria vs placebo and maintains a manageable safety profile in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) receiving background therapy with renin-angiotensin-aldosterone system inhibitors (RAASi), the phase III FINE-ONE trial has shown. These findings represent an important step forward since RAASi were introduced for renoprotection in T1D more than 30 years ago.

In the prespecified subgroup analysis of the VESALIUS-CV trial, evolocumab significantly reduced the risk of first major adverse cardiovascular (CV) events (MACE) in individuals without known significant atherosclerosis and with diabetes.